David Walling, PhD, CNS, MD

Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit, Burden, and Satisfaction in Patients With Schizophrenia

Background: An open-label extension study (NCT02873208) evaluated the long-term tolerability, safety, and efficacy of combination olanzapine/samidorphan (OLZ/SAM) treatment in patients wi...

Leona Bessonova , PhD;

Amy O'Sullivan , PhD;

David McDonnell , MD;

Cory Saucier , MPH;

Michelle White , PhD;

April Foster , BS;

Jakob Bjorner , MD, PhD;

Olga Lapeyra , MD, CCRP;

David Walling , PhD, CNS, MD;

Adam Simmons , MPH;

Julia Carpenter-Conlin , MSW;

10/08/2020

Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil With 1-Day Initiation in Acutely Ill Patients With Schizophrenia

Objective: Evaluate efficacy and safety of a 2-month dose of aripiprazole lauroxil (AL) with a 1-day initiation regimen during hospitalization for an acute exacerbation of schizophrenia. ...

Sergey Yagoda , PhD, MD;

David Walling , PhD, CNS, MD;

Jelena Kunovac , MD;

Amy Claxton , PhD;

Yangchun Du , PhD;

Peter J. Weiden , MD, PhD;

11/22/2019

Efficacy of Monthly Extended-release Risperidone Injections (RBP-7000) for the Treatment of Schizophrenia: An Analysis of Individual PANSS Items

Introduction: RBP-7000 (PERSERIS™) is a once-monthly, subcutaneous, extended-release risperidone formulation that is approved for treating schizophrenia in adults and is designed to deliv...

Anne Andorn , MD;

James Graham , PharmD, BS Pharm, RPh;

Maurizio Fava , MD, PhD;

John Csernansky , MD;

John Newcomer , MD;

Sunita Shinde , MD;

Gilbert Muma , PhD;

Christian Heidbreder , PhD;

David Walling , PhD, CNS, MD;

11/22/2019

Efficacy and Safety of an Asenapine Transdermal System (HP-3070) for Treatment of Adults with Schizophrenia: A Phase 3 Randomized, Placebo-Controlled, Inpatient Study

Background: HP-3070, an asenapine transdermal patch for schizophrenia, offers favorable pharmacokinetics with minimal peak and trough fluctuations.